PD‐L2 Expression in Breast Cancer Promotes Tumor Development and Progression.

Autor: Sun, Yuling¹ (AUTHOR), Yang, Jie¹ (AUTHOR), Chen, Yachun¹ (AUTHOR), Guo, Yundi¹ (AUTHOR), Xiong, Jian¹ (AUTHOR), Guo, Xuqin² (AUTHOR), Zhang, Yawen² (AUTHOR), Gu, Li¹ (AUTHOR), Tong, Min¹ (AUTHOR), Wang, Weipeng² (AUTHOR) wangweipeng@suda.edu.cn, Sun, Jing¹ (AUTHOR) jsun@szhct.edu.cn, Xu, Zhipeng (AUTHOR) zhipengxu@njmu.edu.cn

Publikováno v: Journal of Immunology Research. 7/2/2024, Vol. 2024, p1-11. 11p.

Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective.

Autor: Liu, Rong¹ (AUTHOR) rong.liu@regeneron.com, Yuan, Ying² (AUTHOR), Sen, Suman³ (AUTHOR), Marchenko, Olga⁴ (AUTHOR), Jiang, Qi⁵ (AUTHOR), Tian, Hong⁶ (AUTHOR), Li, Xiaoyun⁶ (AUTHOR), Lin, Ruitao² (AUTHOR), Lu, Cindy⁷ (AUTHOR), Zhou, Heng⁸ (AUTHOR)

Publikováno v: Statistics in Biopharmaceutical Research. Jul-Sep2024, Vol. 16 Issue 3, p338-347. 10p.

Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique

Autor: Robert, C., Mateus, C., Hodi, S., Kefford, R., Hamid, O., Daud, A., Wolchok, J.-D., Hwu, W.-J., Gangadhar, T.-C., Patnaik, A., Joshua, A.-M., Hersey, P., Weber, J., Dronca, R., Zarour, H., Gergich, K., Li, X.-N., Lannone, R., Kang, S.-P., Ebbinghaus, S., Ribas, A.

Publikováno v: In Annales de dermatologie et de venereologie December 2014 141(12) Supplement:S258-S259

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Autor: Ribas A; Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California., Daud A; Department of Hematology/Oncology, University of California-San Francisco, San Francisco., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wolchok JD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Kefford R; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney, Australia., Joshua AM; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Patnaik A; Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio., Hwu WJ; Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston., Weber JS; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida., Gangadhar TC; Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania, Philadelphia., Hersey P; Department of Medicine, University of Sydney, Sydney, Australia., Dronca R; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota., Joseph RW; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida., Zarour H; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., Chmielowski B; Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles., Lawrence DP; Department of Hematology/Oncology, Massachusetts General Hospital, Boston., Algazi A; Department of Hematology/Oncology, University of California-San Francisco, San Francisco., Rizvi NA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Hoffner B; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California., Mateus C; Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France., Gergich K; Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey., Lindia JA; Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey., Giannotti M; Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey., Li XN; BARDS, Merck & Co, Inc, Kenilworth, New Jersey., Ebbinghaus S; Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey., Kang SP; Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey., Robert C; Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.

Publikováno v: JAMA [JAMA] 2016 Apr 19; Vol. 315 (15), pp. 1600-9.

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Autor: Patnaik A; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas. amita.patnaik@start.stoh.com., Kang SP; Merck & Co., Inc., Kenilworth, New Jersey., Rasco D; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Papadopoulos KP; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Elassaiss-Schaap J; Merck & Co., Inc., Kenilworth, New Jersey., Beeram M; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Drengler R; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Chen C; Merck & Co., Inc., Kenilworth, New Jersey., Smith L; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Espino G; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas., Gergich K; Merck & Co., Inc., Kenilworth, New Jersey., Delgado L; Merck & Co., Inc., Kenilworth, New Jersey., Daud A; University of California, San Francisco, San Francisco, California., Lindia JA; Merck & Co., Inc., Kenilworth, New Jersey., Li XN; Merck & Co., Inc., Kenilworth, New Jersey., Pierce RH; Merck & Co., Inc., Kenilworth, New Jersey., Yearley JH; Merck & Co., Inc., Kenilworth, New Jersey., Wu D; Merck & Co., Inc., Kenilworth, New Jersey., Laterza O; Merck & Co., Inc., Kenilworth, New Jersey., Lehnert M; Merck & Co., Inc., Kenilworth, New Jersey., Iannone R; Merck & Co., Inc., Kenilworth, New Jersey., Tolcher AW; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Oct 01; Vol. 21 (19), pp. 4286-93. Date of Electronic Publication: 2015 May 14.